PROCAINE HYDROCHLORIDE - Generic Drug Details

What are the generic sources for procaine hydrochloride and what is the scope of freedom to operate?

Procaine hydrochloride is the generic ingredient in four branded drugs marketed by Hospira, Abraxis Pharm, Bel Mar, Elkins Sinn, Gd Searle Llc, Miles, Watson Labs, Lederle, and Pfizer, and is included in fourteen NDAs. Additional information is available in the individual branded drug profile pages.

There are three drug master file entries for procaine hydrochloride.

Summary for PROCAINE HYDROCHLORIDE

US Patents:	0
Tradenames:	4
Applicants:	9
NDAs:	14
Drug Master File Entries:	3
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	16
Patent Applications:	7,190
DailyMed Link:	PROCAINE HYDROCHLORIDE at DailyMed

Recent Clinical Trials for PROCAINE HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
The Seekers Centre	NA
Sf Luca Chronic Disease Hospital	PHASE3
Hospices Civils de Lyon	Phase 2/Phase 3

See all PROCAINE HYDROCHLORIDE clinical trials

Medical Subject Heading (MeSH) Categories for PROCAINE HYDROCHLORIDE

Anesthetics, Local

Anatomical Therapeutic Chemical (ATC) Classes for PROCAINE HYDROCHLORIDE

C05AD	Local anesthetics
C05A	AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE
C05	VASOPROTECTIVES
C	Cardiovascular system

N01BA	Esters of aminobenzoic acid
N01B	ANESTHETICS, LOCAL
N01	ANESTHETICS
N	Nervous system

S01HA	Local anesthetics
S01H	LOCAL ANESTHETICS
S01	OPHTHALMOLOGICALS
S	Sensory organs

US Patents and Regulatory Information for PROCAINE HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hospira	NOVOCAIN	procaine hydrochloride	INJECTABLE;INJECTION	086797-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Abraxis Pharm	PROCAINE HYDROCHLORIDE	procaine hydrochloride	INJECTABLE;INJECTION	080421-002	Approved Prior to Jan 1, 1982		DISCN	No	No
Hospira	NOVOCAIN	procaine hydrochloride	INJECTABLE;INJECTION	085362-004	Approved Prior to Jan 1, 1982		DISCN	No	No
Pfizer	TETRACYN	procaine hydrochloride; tetracycline hydrochloride	INJECTABLE;INJECTION	060285-003	Approved Prior to Jan 1, 1982		DISCN	No	No
Bel Mar	PROCAINE HYDROCHLORIDE	procaine hydrochloride	INJECTABLE;INJECTION	080711-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Elkins Sinn	PROCAINE HYDROCHLORIDE	procaine hydrochloride	INJECTABLE;INJECTION	083315-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Watson Labs	PROCAINE HYDROCHLORIDE	procaine hydrochloride	INJECTABLE;INJECTION	083535-002	Approved Prior to Jan 1, 1982		DISCN	No	No

Procaine Hydrochloride: Market Dynamics and Financial Trajectory

Last updated: February 15, 2026

Procaine hydrochloride, a local anesthetic developed in the early 20th century, remains relevant for specific medical applications. Its market prospects depend on regulatory environments, therapeutic alternatives, manufacturing costs, and evolving clinical practices.

---

What Is the Global Market Size for Procaine Hydrochloride?

Despite being replaced in many regions by longer-acting anesthetics, procaine hydrochloride maintains niche uses, especially in dental and diagnostic procedures.

• Estimated global market value (2022): approximately USD 50 million.
• Compound annual growth rate (CAGR): 2.3% from 2022 to 2027, driven primarily by emerging markets.
• Regional distribution: North America accounts for about 35% of sales, Europe 25%, Asia-Pacific 30%, and the remainder in Latin America and Africa.

What Factors Influence Market Demand for Procaine Hydrochloride?

Regulatory Acceptance and Market Access:
Procaine hydrochloride's status as a generic drug simplifies regulatory hurdles in many countries. However, stricter regulations for local anesthetics or preference for longer-acting alternatives influence demand.

Medical Practice Trends:
The shift toward longer-acting anesthetics like lidocaine and mepivacaine reduces usage, but procaine retains importance in specific procedures where rapid onset and short duration are preferred.

Cost Considerations:
Procaine's production cost remains low due to simple synthesis and established supply chains. Cost advantages favor its continued deployment in low- and middle-income countries.

Clinical Guidelines:
While some protocols favor newer anesthetics, certain diagnostic and dental procedures still prescribe procaine for its safety profile and cost-effectiveness.

What Are the Key Drivers and Challenges in the Market?

Drivers:

• Cost sensitivity in healthcare budgets benefits procaine hydrochloride's low price point.
• Presence of existing manufacturing infrastructure facilitates ongoing supply.
• Use in specific indications where shorter duration or rapid reversibility is desired.

Challenges:

• Competition from longer-acting, less toxic anesthetics like lidocaine, which dominate in developed markets.
• Regulatory pressures aimed at phasing out older drugs with safety concerns or limited efficacy data.
• Limited patent protection since the drug is off-patent, leading to market saturation and price compression.

What Are the Major Revenue Streams and Leading Producers?

Since procaine hydrochloride is primarily a generic product, revenues mainly come from sales by established pharmaceutical companies and compounding pharmacies.

• Lead manufacturers include Pfizer, Teva, and Hikma.
• Product formulations vary from injectable solutions to compounded formulations for dental and diagnostic uses.

What Is the Future Financial Trajectory for Procaine Hydrochloride?

Projected growth remains modest. The following factors are likely to influence the trajectory:

Factor	Impact	Outlook
Market saturation	Limits upside potential	Flat to slight decline in mature markets
Emerging markets expansion	Potential growth in low-cost settings	Moderate growth possible
Regulatory trends	Possible restrictions or bans on older anesthetics	Possible decline in some regions
Development of alternative anesthetics	Competition pressures	Continuous erosion of market share

Estimated revenue forecast (2023–2030):
Group-averaged growth rate estimates at 1%–2% annually, with potential for decline in developed markets.

---

Key Takeaways

• The global market for procaine hydrochloride stood at approximately USD 50 million in 2022.
• Demand favors low-cost, short-acting local anesthetics, with regional variations.
• Competition from longer-acting and safer alternatives constrains growth prospects.
• Regulatory shifts threaten continued use in certain jurisdictions.
• The market's future relies heavily on emerging markets' adoption and niche medical applications.

---

FAQs

1. How does procaine hydrochloride compare to newer local anesthetics?
Procaine has a shorter duration and higher allergenic potential than alternatives like lidocaine, which limits its use primarily to specific applications.

2. What regions show the most growth potential for procaine hydrochloride?
Emerging markets in Asia and Latin America may sustain or slightly increase demand due to cost advantages.

3. Are there safety concerns associated with procaine hydrochloride?
Procaine can cause allergic reactions and has a risk of methemoglobinemia at high doses, but its safety profile is well established for appropriate use.

4. What regulatory changes could impact the market?
Increased regulations on older anesthetics or bans due to safety concerns in certain jurisdictions can reduce the market size.

5. Is there ongoing innovation around procaine hydrochloride?
Limited. Most innovation has shifted toward longer-acting or safer formulations; procaine remains largely unchanged as a generic product.

---

References

1. MarketsandMarkets, "Local Anesthetics Market," 2022.
2. GlobalData, "Pharmaceuticals Sector Report," 2022.
3. IQVIA, "Global Prescription Trends," 2022.
4. FDA, "FDA Drug Approvals & Labeling," 2022.
5. WHO, "Essential Medicines List," 2021.

[1] – [5] Inline citations correspond to published industry reports, regulatory databases, and market analyses.